Photo from wikipedia
To evaluate the activity of intravesical mitomycin‐C (MMC) to ablate recurrent low‐risk non‐muscle‐invasive bladder cancer (NMIBC) and assess whether it may enable patients to avoid surgical intervention for treatment of… Click to show full abstract
To evaluate the activity of intravesical mitomycin‐C (MMC) to ablate recurrent low‐risk non‐muscle‐invasive bladder cancer (NMIBC) and assess whether it may enable patients to avoid surgical intervention for treatment of recurrence.
Keywords:
bladder cancer;
invasive bladder;
muscle invasive;
non muscle;
risk non;
low risk
Journal Title: Bju International
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Bju International
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!